logo

For the Inventor, By the Inventor

Salt Lake City, UT, United States of America

Myriad Genetics, Inc.


USPTO Granted Patents = 122

% Expired Patents = 36.9



Trademarks = 7

Forward Citations = 1,118

Loading Chart...
Loading Chart...

149 inventors (with patents filed for the assignee):

goldMedal Alexander Gutin (28 out of 33 patents)

silverMedal Alexander Kamb (24 out of 25 patents)

bronzeMedal Sean V Tavtigian (19 out of 26 patents)

4.  Kirsten Timms (17 out of 17 patents)

5.  Victor Abkevich (15 out of 17 patents)

6.  Julia Reid (13 out of 14 patents)

7.  Jerry Lanchbury (12 out of 13 patents)

8.  Steven Stone (12 out of 13 patents)

9.  Susanne Wagner (9 out of 9 patents)

10.  Hwa-Ok Kim (7 out of 17 patents)

11.  Donna Shattuck (7 out of 9 patents)

12.  Thomas M Scholl (7 out of 7 patents)

13.  Mark H Skolnick (7 out of 9 patents)

14.  Paul L Bartel (7 out of 7 patents)

15.  Masakatsu Eguchi (6 out of 28 patents)


Core Competencies:
Cancer Biomarkers
Gene Signatures
Homologous Recombination Deficiency
Hereditary Cancer Genes
Allelic Imbalance
Cancer Prognosis
BRCA2 Mutations
Gene Copy Number Profiling
Tumor Suppressor
Depression Gene
Diabetes Gene
5-FU Assay

122 patents:

1. 12688912 - Artificial intelligence predictive interactivity based on recursive data analysis (2026-07-21),
2. 12680139 - Cancer biomarkers (2026-07-14),
3. 12674207 - Methods and materials for assessing loss of heterozygosity (2026-07-07),
4. 12637716 - Detecting cancer risk (2026-05-26),
5. 12595513 - Methods and materials for assessing loss of heterozygosity (2026-04-07),
6. 12577622 - Detecting cancer risk (2026-03-17),
7. 12421555 - Methods and materials for assessing homologous recombination deficiency (2025-09-23),
8. 12410478 - Hereditary cancer genes (2025-09-09),
9. 12221656 - Methods and materials for assessing homologous recombination deficiency (2025-02-11),
10. 11505832 - Method of using biomarkers and clinical variables for predicting chemotherapy benefit (2022-11-22),
11. 11232850 - Copy number variant caller (2022-01-25),
12. 11225685 - Methods and materials for assessing allelic imbalance (2022-01-18),
13. 11174519 - Method of treating cancer (2021-11-16),
14. 11174517 - Gene signatures for cancer prognosis (2021-11-16),
15. 11104956 - Hereditary cancer genes (2021-08-31),
Myriad Genetics, Inc. is a leading molecular diagnostic company that focuses on genetic testing and providing personalized medicine. They develop and market innovative products to assess an individual's risk for developing diseases, such as cancer, and to tailor treatments based on specific genetic characteristics. Myriad Genetics aims to improve the quality of patients' lives by offering advanced genetic testing solutions and empowering healthcare professionals with critical information to make informed treatment decisions.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Myriad Genetics, Inc.
122 Patents

#7 in Salt Lake City, UT

#29 in Utah

#3,168 in US

#6,547 in the World

Salt Lake City, UT (US)
Salt Lake City, UT, United States of America

Myriad Genetics, Inc.

Forward Citations = 1,118

149 inventors:

goldMedal Alexander Gutin (28 out of 33 patents)

silverMedal Alexander Kamb (24 out of 25 patents)

bronzeMedal Sean V Tavtigian (19 out of 26 patents)

4.  Kirsten Timms (17 out of 17 patents)

5.  Victor Abkevich (15 out of 17 patents)

Please report any incorrect information to [email protected]
Loading…